Rothschild's consolidation play

With more than 2500 entrepreneurial bioscience companies now thought to exist - about 1300 in the U.S., 1000 in Europe and a couple of hundred elsewhere - there is the question of how many of them are sustainable as stand-alone companies.

For years, industry watchers have talked about the need for consolidation where companies with complementary technology are bolted together under one roof. But that trend has never emerged. Rothschild Asset Management is now going to take the bull by the horns, putting together Arrow Healthcare Technology Fund, a $200 million consolidation fund...